Literature DB >> 10751262

Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease.

V Kaasinen1, K Någren, J Hietala, V Oikonen, H Vilkman, L Farde, C Halldin, J O Rinne.   

Abstract

OBJECTIVE: To investigate whether dopamine D2 and D3 receptor subtypes (D2/3Rs) outside the caudate-putamen are affected in PD.
BACKGROUND: Alterations in striatal D2-like dopamine receptors in PD have been extensively demonstrated using PET, but there are no studies focusing on extrastriatal D2/3Rs.
METHODS: Fourteen unmedicated patients with idiopathic early PD with predominantly left-sided symptoms, 14 levodopa-medicated patients with advanced PD, and 20 normal age-matched controls were examined using PET. PET scanning was performed with a novel high-affinity D2/3R radioligand ([11C]FLB 457) and a PET scanner in three-dimensional mode.
RESULTS: In advanced PD, the binding potential of [11C]FLB 457 in the dorsolateral prefrontal cortex was decreased by 40% (p < 0.01), in the anterior cingulate cortex by 20% (p < 0.01), and in the medial thalamus by 17% (p < 0.05) compared with healthy controls. In early PD, the extrastriatal [11C]FLB 457 binding potentials were not significantly different compared with the control group. However, the binding potential in the anterior cingulate cortex (29%; p < 0. 05) was higher in early PD compared with advanced PD.
CONCLUSIONS: These results imply that the D2/3 receptor subtypes outside the striatum are affected in advanced PD but not in the early stages of the disease, and that this receptor decline is present in the anterior cingulate cortex, the dorsolateral prefrontal cortex, and the thalamus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751262     DOI: 10.1212/wnl.54.7.1482

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  Network modulation in the treatment of Parkinson's disease.

Authors:  Kotaro Asanuma; Chengke Tang; Yilong Ma; Vijay Dhawan; Paul Mattis; Christine Edwards; Michael G Kaplitt; Andrew Feigin; David Eidelberg
Journal:  Brain       Date:  2006-07-14       Impact factor: 13.501

2.  Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.

Authors:  S Happe; T Tings; W Koch; J Welsch; K Helmschmied; P C Baier; J Meller; W Wuttke; W Paulus; K Tatsch; C Trenkwalder
Journal:  J Neural Transm (Vienna)       Date:  2006-12-28       Impact factor: 3.575

3.  Characterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET.

Authors:  Sarah A Eisenstein; Jon M Koller; Marilyn Piccirillo; Ana Kim; Jo Ann V Antenor-Dorsey; Tom O Videen; Abraham Z Snyder; Morvarid Karimi; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey
Journal:  Synapse       Date:  2012-05-15       Impact factor: 2.562

Review 4.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 5.  Positron emission tomography in Parkinson's disease: insights into impulsivity.

Authors:  Adam J Stark; Daniel O Claassen
Journal:  Int Rev Psychiatry       Date:  2017-12-05

6.  Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.

Authors:  Silvia Mandel; Gila Maor; Moussa B H Youdim
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 7.  Dopaminergic neurotransmission in the human brain: new lessons from perturbation and imaging.

Authors:  Ji Hyun Ko; Antonio P Strafella
Journal:  Neuroscientist       Date:  2011-05-02       Impact factor: 7.519

8.  Remedial effects of motivational incentive on declining cognitive control in healthy aging and Parkinson's disease.

Authors:  Helga A Harsay; Jessika I V Buitenweg; Jasper G Wijnen; Maria J S Guerreiro; K Richard Ridderinkhof
Journal:  Front Aging Neurosci       Date:  2010-10-15       Impact factor: 5.750

Review 9.  Neuroimaging biomarkers of neurodegenerative diseases and dementia.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

10.  Dopaminergic suppression of brain deactivation responses during sequence learning.

Authors:  Miklos Argyelan; Maren Carbon; Maria-Felice Ghilardi; Andrew Feigin; Paul Mattis; Chengke Tang; Vijay Dhawan; David Eidelberg
Journal:  J Neurosci       Date:  2008-10-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.